Excellent recovery after prolonged heart storage by preservation with coronary oxygen persufflation: orthotopic pig heart transplantations after 14-hr storage.
BACKGROUND
Improvement of heart preservation is still the greatest challenge in preservation research. The unchanged severe restriction of acceptable storage periods of heart grafts since the beginning of clinical heart transplantation indicates that technical innovations are necessary if a substantial improvement is to be achieved.


METHODS
Here, we present the results of hypothermic preservation using the innovative technique of coronary oxygen persufflation (COP). COP simply adds gaseous oxygen to hypothermic graft storage and requires only a "valve guard" for reversible closure of the aortic valve. Fourteen-hr preservation was followed by orthotopic transplantation and evaluations of functional as well as metabolic recovery. Mature pig hearts, a model with restricted preservation tolerance similar to the human heart, were used to guarantee the clinical relevance of this study.


RESULTS
After 14-hr hypothermic storage, COP-preserved hearts were able to recover within 2 hr of cardiopulmonary bypass to a steady cardiovascular function without mechanical or pharmacologic support. The left ventricular pressure amplitude of mHTK-COP-preserved hearts as well as energy charge potential recovered to pregrafting values and the ventricular power output to 66%. Hearts simply stored in University of Wisconsin (UW), modified Bretschneider's histidine-tryptophan-ketoglurate (mHTK), or Euro-Flush with glutathione (EFG) solution had only limited recovery, with significantly lower ventricular power output of 18%, 29% or 30% of pregrafting controls on average.


CONCLUSIONS
Fourteen-hr oxygenated pig heart preservation using COP results in optimal recovery. Storage preservation in solutions containing hyaluronidase (mHTK and EFG) results in higher recoveries as compared to UW solution, an effect that may support the excellent recovery after mHTK-COP preservation.
Fischer
J H
JH
Institute of Experimental Medicine, Department of Cardiothoracic Surgery, University of Cologne, Germany. jh.fischer@uni-koeln.de
Kuhn-Régnier
F
F
Jeschkeit
S
S
Switkowski
R
R
Bardakcioglu
O
O
Sobottke
R
R
Rainer de Vivie
E
E
D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000032:analysis; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D003402:Creatine Kinase / Q000097:blood; D005978:Glutathione / Q000494:pharmacology; D006003:Glycogen / Q000032:analysis; D016027:Heart Transplantation; D006801:Humans; D006931:Hyperbaric Oxygenation; D007118:Immunoassay; D007328:Insulin / Q000494:pharmacology; D007527:Isoenzymes; D009200:Myocardial Contraction / Q000502:physiology; D009206:Myocardium / Q000737:chemistry; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology; D011887:Raffinose / Q000494:pharmacology; D013552:Swine; D013997:Time Factors; D020107:Troponin T / Q000097:blood
D007328:Insulin; D007527:Isoenzymes; D019188:Organ Preservation Solutions; D020107:Troponin T; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D000255:Adenosine Triphosphate; D006003:Glycogen; D003402:Creatine Kinase; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose; D010100:Oxygen